1031619-88-1

Basic information

• Product Name: 3-METHYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-CARBOXYLIC ACID
• Synonyms: 3-METHYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-CARBOXYLIC ACID
• CAS NO: 1031619-88-1
• Molecular Formula: C8H7N3O2
• Molecular Weight: 177.16008
• Mol File: 1031619-88-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-METHYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-CARBOXYLIC ACID(1031619-88-1)
• EPA Substance Registry System: 3-METHYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-CARBOXYLIC ACID(1031619-88-1)

Safety Data

• Hazardous Substances Data: 1031619-88-1(Hazardous Substances Data)

Usage

General Description

3-Methyl[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid is a chemical compound with a molecular formula C7H5N5O2. It is a heterocyclic organic compound that contains a triazolopyridine ring and a carboxylic acid group. 3-METHYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-CARBOXYLIC ACID is commonly used in the synthesis of pharmaceutical drugs and agrochemicals due to its potential biological activities. It is also a key intermediate for the preparation of various bioactive molecules and functional materials. The compound has been studied for its potential antimicrobial, antifungal, and antiviral properties, making it a valuable molecule in the pharmaceutical industry.

Upstream product

• 108281-78-3 6-bromo-3-methyl-1,2,4-triazolo<4,3-a>pyridine 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 133081-24-0 6-hydrazinylnicotinic acid 
• 64-19-7 acetic acid 

Relevant articles and documents

Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype

This Letter details our efforts to discover structurally unique M4 PAMs containing 5,6-heteroaryl ring systems. In an attempt to improve the DMPK profiles of the 2,3-dimethyl-2H-indazole-5-carboxamide and 1-methyl-1H-benzo[d][1,2,3]triazole-6-carboxamide cores, we investigated a plethora of core replacements. This exercise identified a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide core that provided improved M4 PAM activity and CNS penetration.

INDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Keeping it small, polar, and non-flat: diversely functionalized building blocks containing the privileged 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]- and [1,5-a]pyridine cores

Six sets of functionalized building blocks based on 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine as well as 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridine cores have been prepared. These compounds are non-flat, bicyclic heterocycles that are likely to find utility as privileged motifs for lead-like compound design. One set of building blocks, (5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-6-ylmethyl)amines, proved useful as a scaffold for developing compounds that stimulate glucagon-like peptide-1 (GLP-1) secretion and are novel anti-diabetes drug leads.